Biblio Discovery — Demo Discovery Service

9 hasil untuk "Gunneri, Subbareddy"

Menampilkan 1–9 · 0,62 detik · RSS

  1. Artikel Jurnal Teks lengkap

    A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9–12 month old healthy infants

    Thuluva, Subhash; Gunneri, SubbaReddy; Turaga, Kishore dkk.

    Contemp Clin Trials Commun · 2023 · Inggris · PubMed Central

    Measles is a major cause of childhood mortality and one-third of the world's Measles deaths occur in India. Rubella causes lifelong birth defects (Congenital Rubella Syndrome). Although neither condition has a cure, the MR vaccination can successfully prevent both diseases. The safety of Biological…

  2. Artikel Jurnal Teks lengkap

    Immunogenicity and safety of a multi-human dose formulation of Biological E’s 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14(®)) administered to 6–8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled study

    Thuluva, Subhash; Matur, Ramesh V.; Gunneri, Subbareddy dkk.

    Front Immunol · 2025 · Inggris · PubMed Central

    BACKGROUND: Pneumococcal conjugate vaccines (PCVs) have considerably reduced the burden of invasive pneumococcal disease (PD) worldwide. Consequently, though, there has been an increase in non-vaccine serotype-induced PD particularly at both the extremes of age. Biological E has developed a…

  3. Artikel Jurnal Teks lengkap

    Safety and immunogenicity of Biological E's typhoid conjugate vaccine TYPHIBEV(Ⓡ) concomitantly administered with measles rubella vaccine: a phase IV prospective, multicenter study

    Thuluva, Subhash; Matur, Ramesh V; Gunneri, SubbaReddy dkk.

    IJID Reg · 2025 · Inggris · PubMed Central

    OBJECTIVES: Typhoid infections remain one of the major health concerns worldwide. Vaccines that prevent typhoid, particularly, the conjugated polysaccharide ones, are an important tool in addressing this major health concern. Here, we report on the safety profile of Biological E's TYPHIBEV(Ⓡ) when…

  4. Artikel Jurnal Teks lengkap

    Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: a phase 3, single-blind, randomised controlled trial

    Thuluva, Subhash; Paradkar, Vikram; Gunneri, SubbaReddy dkk.

    Lancet Reg Health Southeast Asia · 2025 · Inggris · PubMed Central

    BACKGROUND: The SARS-CoV-2 virus continues to evolve with recent variants such as the omicron sub-variants potentially exhibiting increased transmissibility. Of note, the XBB.1.5 variant has been associated with vaccine-breakthrough cases. We utilised the same platform previously used to develop…

  5. Artikel Jurnal Teks lengkap

    Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A prospective double-blind randomized phase III clinical study

    Thuluva, Subhash; Paradkar, Vikram; Gunneri, SubbaReddy dkk.

    IJID Reg · 2025 · Inggris · PubMed Central

    OBJECTIVES: Vaccines against COVID-19 significantly reduced symptomatic disease and hospitalization. However, waning and diminished protection against emerging variants of concern (VoCs) have warranted booster doses. Clinical studies comparing homologous and heterologous boosters demonstrate…

  6. Artikel Jurnal Teks lengkap

    Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial

    Thuluva, Subhash; Matur, Ramesh V.; Gunneri, Subbareddy dkk.

    Lancet Reg Health Southeast Asia · 2026 · Inggris · PubMed Central

    BACKGROUND: Pneumococcal conjugate vaccines (PCVs) have markedly reduced childhood pneumococcal diseases, yet serotype replacement and regional heterogeneity remain important challenges. The World Health Organization recommends either a 3p + 0 or 2p + 1 schedule for PCV immunization programmes…

  7. Artikel Jurnal Teks lengkap

    Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial

    Thuluva, Subhash; Paradkar, Vikram; Gunneri, SubbaReddy dkk.

    Hum Vaccin Immunother · 2023 · Inggris · PubMed Central

    Optimum formulation of Biological-E’s protein subunit CORBEVAX™ vaccine was selected in phase-1 and -2 studies and found to be safe and immunogenic in healthy adult population. This is a phase-3 prospective, single-blinded, randomized, active controlled study conducted at 18 sites across India in…